|
Therapy area
Bone degradation diseases including
osteoporosis, osteoarthritis and skeletal
metastases.
|
|
Phase
Two CD's (candidate drug), MIV-710 in preclinical development phase. |
Competitive edge
Cathepsin K inhibitors markedly decrease
degradation of bone without affecting bone
formation, which is expected to lead to improved
strength of the skeleton. Rapid onset and offset of
inhibitory activity on bone resorption is a marked
advantage over current commonly prescribed
pharmaceuticals. |
Project data
- Highly potent and selective cathepsin K inhibitor which inhibits bone resorption (bone loss)
- The important bone formation process is maintained
- Long effect duration in preclinical models
- Very favourable pharmacokinetic properties of CD results in a low dose and a once daily treatment
|
